Table 2. In Vitro Frameshifting Assays.
| SARS-CoV-2 |
RSV |
|||
|---|---|---|---|---|
| Sample | Frameshifting | Translation | Frameshifting | Translation |
| WT | 0.99 ± 0.02 | 1.11 ± 0.14 | 0.97 ± 0.04 | 1.09 ± 0.11 |
| WT + DMSO | 1.00 ± 0.00a | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 |
| 5′ controlb | 0.09 ± 0.02 | 1.05 ± 0.24 | 0.05 ± 0.04 | 0.98 ± 0.14 |
| 3′ control | 0.01 ± 0.01 | 0.97 ± 0.29 | 0.06 ± 0.05 | 0.61 ± 0.35 |
| SF control | 1.24 ± 0.05 | 1.20 ± 0.32 | 4.69 ± 0.62 | 0.94 ± 0.20 |
| WT + MTDB | 1.02 ± 0.04 | 1.01 ± 0.20 | 1.13 ± 0.04 | 0.96 ± 0.13 |
| WT + 1 | 0.99 ± 0.03 | 1.35 ± 0.23 | 1.21 ± 0.04 | 0.77 ± 0.01 |
| WT + 13 | 0.98 ± 0.02 | 0.98 ± 0.14 | 1.13 ± 0.03 | 0.82 ± 0.01 |
| WT + Merafloxacin | 0.21 ± 0.01 | 0.90 ± 0.07 | 0.59 ± 0.21 | 0.70 ± 0.07 |
a
Frameshifting and translation are reported normalized to values obtained for the WT frameshifting pseudoknot sequences in the presence of DMSO (see Supplementary Methods). Values are reported as mean ± SD (n = 3).
b
Controls include a stop codon placed 5′ to the pseudoknot sequence (5′ control), a stop codon placed 3′ to the pseudoknot sequence (3′ control), and the two luciferases placed in the same frame (SF control).